Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals

Bone

Volumn 57, Issue 2, 2013, Pages 437-442

  Maggio, Marcello ^a,b   Lauretani, Fulvio ^b   Ceda, Gian Paolo ^a,b   De Vita, Francesca ^b   Bondi, Giuliana ^a   Corsonello, Andrea ^c   Cattabiani, Chiara ^d   Lattanzio, Fabrizia ^c   Ruggiero, Carmelinda ^e   Nouvenne, Antonio ^b   Meschi, Tiziana ^a,b   Bandinelli, Stefania ^f   Ferrucci, Luigi ^g  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c INRCA   (Italy)

^d Azienda USL Piacenza   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f Local Health Agency of Florence   (Italy)

^g NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Bone mineral density; Elderly; InCHIANTI Study; Proton pump inhibitors; Trabecular bone mineral density

Indexed keywords

CALCIUM; ESTRADIOL; INTERLEUKIN 6; PARATHYROID HORMONE; PROTON PUMP INHIBITOR; SOMATOMEDIN C; TESTOSTERONE; VITAMIN D;

AGED; ARTICLE; BONE DENSITY; BONE STRENGTH; CHRONIC DRUG ADMINISTRATION; COMMUNITY SAMPLE; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL BONE; CORTICAL CROSS SECTIONAL AREA; DISEASE ASSOCIATION; DRUG USE; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; OSTEOPOROSIS; PEPTIC ULCER; RISK ASSESSMENT; RISK FACTOR; SELF REPORT; TRABECULAR BONE; TRABECULAR CROSS SECTIONAL AREA; TREATMENT OUTCOME;

BONE MINERAL DENSITY; ELDERLY; INCHIANTI STUDY; PROTON PUMP INHIBITORS; TRABECULAR BONE MINERAL DENSITY;

AGED; BONE AND BONES; BONE DENSITY; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROTON PUMP INHIBITORS;

EID: 84885825052     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.09.014     Document Type: Article

References (52)

1. Pilotto A., Franceschi M., Leandro G., Scarcelli C., D'Ambrosio L.P., Seripa D., et al. Clinical features of reflux esophagitis in older people: a study of 840 consecutive patients. J Am Geriatr Soc 2006, 54:1537-1542.
2. Bhatt D.L., Scheiman J., Abraham N.S., Antman E.M., Chan F.K., Furberg C.D., et al. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008, 118:1894-1909. [Erratum in: Circulation. 122 (2010) e438].
3. Bashford J.N., Norwood J., Chapman S.R. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998, 317:452-456.
4. McCarthy D.M. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010, 26:624-631.
5. Forgacs I., Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008, 336:2-3.
6. Naunton M., Peterson G.M., Bleasel M.D. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000, 25:333-340.
7. Mat Saad A.Z., Collins N., Lobo M.M., O'Connor H.J. Proton pump inhibitors: a survey of prescribing in an Irish general hospitalì. Int J Clin Pract 2005, 59:31-34.
8. Walker N.M., McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001, 23:116-117.
9. Grant K., Al-Adhami N., Tordoff J., Livesey J., Barbezat G., Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci 2006, 28:189-193.
10. Pasina L., Nobili A., Tettamanti M., Salerno F., Corrao S., Marengoni A., et al. REPOSI Investigators. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med 2011, 22:205-210.
11. Laheij R.J., Sturkenboom M.C., Hassing R.J., Dieleman J., Stricker B.H., Jansen J.B. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292:1955-1960.
12. Rodríguez L.A., Ruigómez A., Wallander M.A., Johansson S. Acid-suppressive drugs and community-acquired pneumonia. Epidemiology 2009, 20:800-806.
13. Sultan N., Nazareno J., Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol 2008, 22:761-766.
14. Johnstone J., Nerenberg K., Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010, 31:1165-1177.
15. Bavishi C., Dupont H.L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011, 34:1269-1281.
16. Howell M.D., Novack V., Grgurich P., Soulliard D., Novack L., Pencina M., et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010, 170:784-790.
17. Linsky A., Gupta K., Lawler E.V., Fonda J.R., Hermos J.A., Linsky A., et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010, 170:772-778. [Erratum in: Arch. Intern. Med. 170 (2010) 1100].
18. Abraham N.S. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol 2012, 28:615-620.
19. Regolisti G., Cabassi A., Parenti E., Maggiore U., Fiaccadori E. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis 2010, 56:168-174.
20. Charlot M., Grove E.L., Hansen P.R., Olesen J.B., Ahlehoff O., Selmer C., et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011, 342:d2690.
21. Abrahamsen B., Eiken P., Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011, 171:998-1004.
22. Maggio M., Corsonello A., Ceda G.P., Cattabiani C., Lauretani F., Buttò V., et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med 2013, 173:518-523.
23. U.S. Food and drug Administration: possible fracture risk with high dose, long-term use of proton pump inhibitors Available from, [Accessed March 15, 2011]. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm213206.htm.
24. Yu E.W., Bauer S.R., Bain P.A., Bauer D.C. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011, 124:519-526.
25. Kwok C.S., Yeong J.K., Loke Y.K. Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011, 48:768-776.
26. Russo C.R., Lauretani F., Bandinelli S., Bartali B., Di Iorio A., Volpato S. Aging bone in men and women: beyond changes in bone mineral density. Osteoporos Int 2003, 14:531-538.
27. Lauretani F., Bandinelli S., Griswold M.E., Maggio M., Semba R., Guralnik J.M., et al. Longitudinal changes in BMD and bone geometry in a population-based study. J Bone Miner Res 2008, 23:400-408.
28. Ferrucci L., Bandinelli S., Benvenuti E., Di Iorio A., Macchi C., Harris T.B., et al. Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc 2000, 48:1618-1625.
29. Lauretani F., Bandinelli S., Russo C.R., Maggio M., Di Iorio A., Cherubini A., et al. Correlates of bone quality in older persons. Bone 2006, 39:915-921.
30. Pahor M., Chrischilles E.A., Guralnik J.M., Brown S.L., Wallace R., Carbonin P.U. Drug data coding and analysis in epidemiologic studies. Eur J Clin Epidemiol 1994, 10:405-411.
31. Siris E.S., Miller P.D., Barrett-Connor E., Faulkner K.G., Wehren L.E., Abbott T.A., et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001, 286:2815-2822.
32. Vermeulen A., Verdonck L., Kaufman J.M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84:3666-3672.
33. Pisani P., Faggiano F., Krogh V., Palli D., Vineis P., Berrino F. Relative validity and reproducibility of a food frequency dietary questionnaire for use in the Italian EPIC centres. Int J Epidemiol 1997, 26:S152-S160.
34. Bartali B., Turrini A., Salvini S., Lauretani F., Russo C.R., Corsi A.M., et al. Dietary intake estimated using different methods in two Italian older populations. Arch Gerontol Geriatr 2004, 38:51-60.
35. Lau Y.T., Ahmed N.N. Fracture risk and bone mineral density reduction associated with proton pump inhibitors. Pharmacotherapy 2012, 32:67-79.
36. Gray S.L., aCroix L.A.Z., Larson J., Robbins J., Cauley J.A., Manson J.E., et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010, 170:765-771.
37. Yu E.W., Blackwell T., Ensrud K.E., Hillier T.A., Lane N.E., Orwoll E. Acid suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008, 83:251-259.
38. Targownik L.E., Lix L.M., Leung S., Leslie W.D. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010, 138:896-904.
39. Ozdil K., Kahraman R., Sahin A., Calhan T., Gozden E.H., Akyuz U., et al. Bone density in proton pump inhibitors users: a prospective study. Rheumatol Int 2013, 33:2255-2260.
40. Targownik L.E., Leslie W.D., Davison K.S., Goltzman D., Jamal S.A., Kreiger N., et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012, 107:1361-1369.
41. Chen H., Zhou X., Fujita H., Onozuka M., Kubo K.Y. Age-related changes in trabecular and cortical bone microstructure. Int J Endocrinol 2013, 2013:213-234.
42. Rittweger J., Beller G., Ehrig J., Jung C., Koch U., Ramolla J., et al. Bone-muscle strength indices for the human lower leg. Bone 2000, 27:319-326.
43. Valuck R.J., Ruscin J.M. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004, 57:422-428.
44. Marcuard S.P., Albernaz L., Khazanie P.G. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994, 120:211-215.
45. Recker R.R. Calcium absorption and achlorhydria. N Engl J Med 1985, 313:70-73.
46. Undy T.C., Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol 2008, 69:338-341.
47. Hoorn E.J., van der Hoek J., de Man R.A., Kuipers E.J., Bolwerk C., Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010, 56:112-116.
48. Yang Y.X. Chronic proton pump inhibitor therapy and calcium metabolism. Curr Gastroenterol Rep 2012, 14:473-479.
49. Faulhaber G.A., Furlanetto T.W. Could magnesium depletion play a role on fracture risk in PPI users?. Arch Intern Med 2010, 170:1776.
50. Verdú E.F., Fraser R., Armstrong D., Blum A.L. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers. Scand J Gastroenterol 1994, 29:1065-1069.
51. Saito M., Fujii K., Marumo K. Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 2006, 79:160-168.
52. McLean R.R., Jacques P.F., Selhub J., Tucker K.L., Samelson E.J., Broe K.E., et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004, 350:2042-2049.